Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that.
Semaglutide and gastric emptying, from the point of view of someone who has read the documentation and is still stuck.
Saying which parts I have understood so that nobody wastes time re-explaining them, and where exactly the understanding stops.
Following this. I have the same question and no better information than the first post.
Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.
One of those cases where knowing the mechanism does not help the decision.
Picking up post #4: that is the part I would want checked first.
Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.
On post #2 — agreed on the reasoning, with one qualification.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
If anyone has run this properly I would rather read that than my own guess.
The failure mode on semaglutide and gastric emptying is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Counter-ion form matters for the arithmetic and is almost never stated. A vial labelled 5 mg of peptide as an acetate salt and one labelled 5 mg as trifluoroacetate do not contain the same quantity of the molecule you are interested in.
I have written this out at length because the short version keeps being misread.
This settles it for me, at least until somebody posts a reason it should not.
I read post #9 twice before replying, because I had assumed the opposite.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
Written quickly, so the reasoning may be tighter than the wording.
Post #13 answers the question as asked. The question underneath it is different.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Noting that the question and the thing people usually mean by it are different.
Practical note on semaglutide and gastric emptying: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
I disagree with the framing of semaglutide and gastric emptying above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Coming back to post #13, because the follow-up matters more than the original answer.
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
The variance between people here is larger than the effect being discussed.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
I would put moderate confidence on the mainstream reading of semaglutide and gastric emptying and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Adding the measurement that post #18 says would settle it.
Filing a mild objection to the consensus on semaglutide and gastric emptying. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Post #21 describes the usual case. This is about the unusual one.
Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but trial data is absent and off-label dosing enters territory this site does not advise on.
A partial answer, offered because a partial answer beats none.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
This is the sort of thing the wiki should carry and currently does not.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
The arithmetic in post #22 is right; the assumption feeding it is the part to check.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
The uncertainty is in the assumption, not in the calculation.
Grateful for the specificity. Vague answers to this question are what sent me looking.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Happy to be corrected if someone holds better data than mine.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.